QT-019C

CD19 and BCMA-targeted CAR T-cell therapy · Institute of Hematology & Blood Diseases Hospital

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for QT-019C, covering 2026-01-20 to 2026-01-20. Get the full timeline:

Most recent: Clinical Trial Update: CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases [Phase 1]

See pricing